INVESTORS
Liverpool ChiroChem (LCC) is a leader in chiral chemistry drug discovery with a validated novel and diverse proprietary chemistry platform.
Paul Colbon, CEO & Co-Founder.
LCC has built and validated a chiral chemistry platform over 10 years across multiple drug target classes, including kinases, GPCRs, DUBs, and now mRNA small molecule targets
Proprietary chemical space of >1-billion novel, diverse, chiral small molecules
PACE™ technology platform validated through fee for service relationships with 13 of the top 20 pharmaceutical companies
Automated high throughput capabilities with a team of 30 staff capable of producing 1,000 drug samples per month